To report 6 patients taking oral vitamin K1 (phytonadione) to reduce warfarin's activity.
Case Summary:
Six patient cases are summarized in which oral vitamin K1 was used to reduce the international normalized ratio (INR) in patients at risk of bleeding.
Discussion:
The use of oral vitamin K1 to antagonize warfarin's effects is discussed, as well as the benefits of oral vitamin K1 administration and the disadvantages of parenteral vitamin K1 administration. In addition, an extensive literature review of the discovery and clinical development of warfarin and vitamin K1 is described.
Conclusions:
In patients receiving warfarin therapy who have an increased INR and are at risk of bleeding, oral vitamin K1 therapy may be safer, less painful, and more cost-effective than the traditional parenteral route of administration.
Get full access to this article
View all access options for this article.
References
1.
HirshJ, DalenJE, DeykinD, PollerL.Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest1992; 102(suppl):312S–26S.
2.
PengoV, BanzatoA, GarelliE, ZassoA, BiasioloA.Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation. Blood Coagul Fibrinolysis1993; 4: 739–41.
3.
de la RubiaJ, GrauE, MontserratI, ZuazuI, PayáA.Anaphylactic shock and vitamin K1 (letter). Ann Intern Med1989; 110: 943.
Product information: Mephyton (phytonadione). West Point, PA: Merck, 1991.
9.
LinkKP. The discovery of dicumarol and its sequels. Circulation1959; 19: 97–107.
10.
CampbellHA, LinkKP. Studies on the hemorrhagic sweet clover disease: the isolate and crystallization of the hemorrhagic agent. J Biol Chem1941; 138: 21–33.
11.
StahmannMA, HuebnerCF, LinkKP. Studies on the hemorrhagic sweet clover disease: identification and synthesis of the hemorrhagic agent. J Biol Chem1941; 138: 513–27.
12.
OvermanRS, StahmannMA, HuebnerCF, SullivanWR, SperoL, DohertyDGStudies on the hemorrhagic sweet clover disease: anticoagulant activity and structure in the 4-hydroxycoumarin group. J Biol Chem1944; 153: 5–24.
13.
HolmesRW, LoveJ.Suicide attempt with warfarin, a bishydroxycoumarin-like rodenticide. JAMA1952; 148: 935–7.
ClatanoffDV, TriggsPO, MeyerOO. Clinical experience with coumarin anticoagulants warfarin and warfarin sodium. Arch Intern Med1954; 97: 213–20.
16.
WolffJM, BarkerNW, GifferdRW, MannFD. Experience with a new intravenous coumarin anticoagulant (warfarin, sodium derivative). Proc Mayo Clin1953; 28: 489–97.
17.
ShapiroS, CiferriFE. Intramuscular administration of the anticoagulant warfarin (Coumadin) sodium. JAMA1957; 165: 1377–80.
18.
FremontRE, JagendorfB.Clinical observations on use of warfarin (Coumadin) sodium, a new anticoagulant. JAMA1957; 165: 1381–8.
19.
PollockBE. Clinical experience with warfarin (Coumadin) sodium, a new anticoagulant. JAMA1955; 159: 1094–7.
20.
SuttieJW. Warfarin and vitamin K. Clin Cardiol1990; 13: 16–8.
21.
MajerusPW, BrozeGJ, MiletichJP, TollefsenDM. Anticoagulant, thrombolytic, and antiplatelet drugs. In: GilmanAG, RallTW, NiesAS, TaylorP eds. Goodman and Gilman's the pharmacological basis of therapeutics. New York: Pergamon Press, 1990: 1317–9.
22.
DamH.Hæmorrhages in chicks reared on artificial diets: a new deficiency disease. Nature1934; 133: 909–10.
23.
DamH.The antihæmorrhagic vitamin of the chick. Nature1935; 135: 652–3.
24.
WarnerED, BrinkhousKM, SmithHP. Bleeding tendency of obstructive jaundice: prothrombin deficiency and dietary factors. Soc Exp Biol Med Proc1938; 37: 628–30.
25.
MarcusR, CoulstonAM. Fat-soluble vitamins. In: GilmanAG, RallTW, NiesAS, TaylorP eds. Goodman and Gilman's the pharmacological basis of therapeutics. New York: Pergamon Press, 1990:1563.
26.
O'ReillyRA. Vitamin K and oral anticoagulant drugs as competitive antagonists in man. Pharmacology1972; 7: 149–58.
